Dare Bioscience shares are trading higher after Brookline Capital upgraded the stock from Hold to Buy and announced a $3 price target.
Portfolio Pulse from Benzinga Newsdesk
Dare Bioscience shares are trading higher following an upgrade from Brookline Capital, which changed its rating from Hold to Buy and set a $3 price target.
May 15, 2024 | 11:58 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Dare Bioscience shares are trading higher after Brookline Capital upgraded the stock from Hold to Buy and set a $3 price target.
The upgrade from Brookline Capital from Hold to Buy and the new price target of $3 is likely to boost investor confidence and drive the stock price higher in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100